Evidence-based insights into peptide protocols, safety research, and optimization strategies. Built on clinical rigor, powered by community knowledge.
Get weekly insights on peptide protocols, safety updates, and optimization strategies delivered to your inbox.
No spam. Unsubscribe anytime. Clinical rigor, always.
35+
Articles
18
Categories
Deep dives into peptide science — evidence-graded, honestly reported
The same TRT protocol becomes a fundamentally different risk proposition at 30 than at 50. Here's where the calculus shifts, and where peptides start winning specific trades.
After 35, cardiovascular remodeling accelerates, prostate risk compounds, and HPTA recovery narrows. This article maps the age-stratified risk data for TRT and identifies where GH secretagogues, the Wolverine Stack, and Sermorelin offer lower-cost alternatives for specific outcomes.
Comprehensive outcome research with safety data and practical protocol references
Detailed compound profiles with mechanisms, safety data, and dosing protocols
Cardiac peptide therapy isn't science fiction — Tβ4 has completed Phase 2 in acute MI (NCT05984134), and SS-31 sits in advanced-phase trials for mitochondrial heart disease.
A plain-English look at the peptides being investigated for cardiovascular repair — Thymosin β4 for post-infarct tissue regeneration, elamipretide for mitochondrial membrane stability, and the adjacent vascular-bioregulator layer.
Mitochondria-derived peptides like SS-31 and MOTS-c are rewriting the rules of cellular energy — but the translational gap between mouse models and human performance remains wide open.
The mitochondrial revolution is moving beyond generic antioxidants toward precision peptides that stabilize the inner membrane and restore fading cellular signals. SS-31 tightens the elastic of the cell while MOTS-c acts as an exercise mimetic encoded in our own DNA — yet clinical reality checks remind us that promising preclinical data does not always survive the journey to the pharmacy.
A D-retro-inverso peptide that selectively kills senescent cells by disrupting the FOXO4-p53 survival interaction, triggering mitochondrial apoptosis in aged 'zombie' cells while sparing healthy tissue.
FOXO4-DRI breaks the molecular shield that keeps senescent cells alive. By freeing p53 from FOXO4 sequestration, it triggers selective apoptosis in aged cells, restoring kidney function, testosterone levels, and tissue vitality in preclinical models.
A synthetic heptapeptide that acts as a molecular GPS for your body's repair crew — directing cell migration, building new blood vessels into injured tissue, and potentially re-activating embryonic healing pathways.
TB-500 is the synthetic analog of Thymosin Beta-4, a naturally occurring protein involved in actin regulation, cell migration, and tissue repair. Its unique mechanism targets the body's internal repair logistics rather than just providing raw materials.
A 15-amino-acid gastric pentadecapeptide that coordinates multi-system repair through angiogenesis, collagen synthesis, and gut-brain axis stabilization.
BPC-157 is a synthetic peptide derived from human gastric juice, notable for its extreme biochemical stability and capacity to coordinate tissue repair across musculoskeletal, vascular, and neurological systems.